MedTrace Logo

Prevalence of Pulmonary Hypertension (PAH) in Patients With Thalassemia

NCT01496963 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1500

Last updated 2022-08-04

No results posted yet for this study

Summary

This is a multicenter observational case-control analysis lasting 12 months aimed at determining the prevalence of pulmonary hypertension (PAH) in patients with Thalassemia Major and Intermedia. The patients will be followed, treated and examined according to the best standard clinical practice dictated by the Italian Society for the study of Hemoglobinopathies (SITE), Thalassemia International Federation (TIF)and the Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC); European Respiratory Society (ERS); International Society of Heart and Lung Transplantation (ISHLT) guidelines.

Conditions

Interventions

OTHER

Physician standard-of-care according to ESC/ERS Guidelines

Physician standard-of-care

Sponsors & Collaborators

  • Ente Ospedaliero Ospedali Galliera

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01496963 on ClinicalTrials.gov